
    
      Prospective, multicentre, open label, phase II clinical trial with diagnostic
      radiopharmaceutical on efficacy and tolerability of 18F or 68Ga labelled RGD peptide for
      detection of malignant tissues expressing integrins, to predict the therapeutic response of
      lesions of advanced head and neck cancer or advanced non-small cells lung cancer to treatment
      including an agent with antiangiogenic effect.
    
  